Erenumab for Idiosyncratic Facial Pain

Rhinosinusitis Clinical Trial

Official title:

A Randomized, Double-Blinded, Single Site Study to Evaluate the Efficacy of Erenumab for Treatment of Idiosyncratic Facial Pain Mimicking Rhinosinusitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04249427
• Other study ID #: Pro00104284
• Status: Completed
• Phase: Phase 4
• Start date: February 10, 2021
• Est. completion date: July 11, 2023

Study information

• Verified date: August 2023
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase IV randomized, double-blinded, placebo-controlled study to evaluate the efficacy of Erenumab in subjects with midfacial pain or pressure, without clinical or radiographic evidence of sinusitis.

Description:

Eligible participants are randomized to receive either Erenumab or placebo by subcutaneous injection once monthly for 6 months. Study duration is eight months which includes a 30 day screening/lead-in period and 6 monthly treatment visits followed by a follow-up visit one month following the last dose of study drug administration. Participants will be expected to score on a scale of 1 to 10 their symptoms of facial pain/pressure, nasal congestion, and rhinorrhea as well well as any rescue medicines taken for pain each day via a mobile app.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: July 11, 2023
• Est. primary completion date: July 11, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults 18 years of age and older presenting to Duke Head & Neck Surgery and Communications Sciences clinic for evaluation of rhinosinusitis and/or facial pain or pressure.

2. Symptoms are present at least 10 days a month for the last 3 months as reported by subject.

3. Symptoms must include midfacial pain or uncomfortable pressure (may be unilateral or bilateral), which is defined as pain in the regions overlying the maxillary, ethmoid, frontal sinuses either together or individually.

4. Nasal endoscopy in the last three months shows no signs of inflammation (i.e. thick drainage, polyps, watery edema in the middle meatus or spheno-ethmoid recess (mild edema permitted).

5. Sinus CT scan or MRI within 12 months of enrollment during a symptomatic period shows no more than scattered minimal mucosal edema or mucous retention cyst with patent infundibula bilaterally. For subjects with a CT scan more than 12 months old or just an MRI, a CT will be repeated for study purposes. For patients with CT scans less than 12 months old, a CT will be repeated for study purposes if the subject has changes in symptoms suggestive of sinusitis.

6. Ability to read/write English.

7. Has a smart phone, ipod or iPad touch for completion of the EMA on a daily basis.

Exclusion Criteria:

1. Hypersensitivity to erenumab or to any of the drug components (acetate, polysorbate, and sucrose).

2. Previous exposure to erenumab or any other CGRP inhibitor in the six months prior to treatment.

3. Allergy to latex.

4. Inability to differentiate facial pain from other headaches.

5. Non-English speaking or unable to provide written informed consent.

6. On a preventative migraine medication (see below) during the 30 day lead-in period:

• Category 1: Divalproex sodium, sodium valproate

• Category 2: Topiramate

• Category 3: Beta blockers (for example: atenolol, bisoprolol, metoprolol, nadolol, ebivolol, pindolol, propranolol, timolol)

• Category 4: Tricyclic antidepressants (for example: amitriptyline, nortriptyline, protriptyline)

• Category 5: Serotonin-norepinephrine reuptake inhibitors (for example:

venlafaxine, desvenlafaxine, duloxetine, milnacipran)

• Category 6: Flunarizine, verapamil

• Category 7: Lisinopril, candesartan

7. Received botulinum toxin (Botox) to the head and neck for migraines in the last four months.

8. More than one major open surgery of the nose or sinuses for sinonasal cancer.

9. History of uncontrolled or unstable blood pressure.

10. History of liver failure.

11. History of metastatic malignancy in the last five years or actively undergoing treatment for cancer.

12. Active seizure disorder or other significant neurological conditions other than migraine.

13. Myocardial infarction (MI), stroke, transient ischemic attack (TIA), unstable angina, or coronary artery bypass surgery or other revascularization procedure within 12 months prior to screening.

14. History or evidence of any other unstable or clinically significant medical condition that in the opinion of the sponsor-investigator/ Principal Investigator, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.

15. Evidence of drug or alcohol abuse or dependence within 12 months prior to screening, based on medical records or patient self-report.

16. Pregnant or breastfeeding, or expecting to conceive during the study, including through 16 weeks after the last dose of investigational product or placebo

17. Female subject of childbearing potential who is unwilling to use an acceptable method of effective contraception during treatment with investigational product or placebo through 16 weeks after the last dose of investigational product. Female subjects not of childbearing potential are defined as any female who is post-menopausal by history, defined as:

• Age = 55 years with cessation of menses for 12 or more months, OR

• Age < 55 years but no spontaneous menses for at least 2 years, OR

• Underwent bilateral oophorectomy, bilateral salpingectomy, or hysterectomy

18. Unlikely to be able to complete all protocol required study visits or procedures.

19. Currently receiving treatment in another investigational device or drug study.

Related Conditions & MeSH terms

• Facial Pain
• Facies
• Rhinosinusitis

Intervention

Drug:
• Erenumab Prefilled Syringe
140mg Erenumab, pre-filled syringe given by subcutaneous injection

Other:
• Placebo
Placebo, pre-filled syringe given by subcutaneous injection

Locations

Country	Name	City	State
United States	Duke University Medical Center and affiliated practices	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
David Jang, M.D.	Amgen

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in mean number of days per month with significant mid-facial pain or pressure	change in number of days per month with significant mid-facial pain or pressure (defined as greater than 4/10 on scale of 1 - 10) measured by daily dairy completion	Baseline, 1,3, and 6 months
Secondary	Change in SNOT-22	Measured by SNOT-22 survey completion	Baseline, 1, 3 and 6 months
Secondary	Change in Physical Function	Measured by Migraine Function Impact Questionnaire (MFIQ) survey completion	Baseline, 1, 3 and 6 months
Secondary	Change in Usual Activities	Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion	Baseline, 1, 3 and 6 months
Secondary	Change in Social Function	Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion	Baseline, 1, 3 and 6 months
Secondary	Change in Emotional Function	Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion	Baseline, 1, 3 and 6 months
Secondary	Change in Overall Impact (global)	Measured by Migraine Functional Impact Questionnaire (MFIQ) survey completion	Baseline, 1, 3 and 6 months
Secondary	Change in average number of days per month with significant nasal congestion	Measured by daily diary completion via mobile app	Baseline, 1, 3 and 6 months
Secondary	Change in average number of days per month with significant rhinorrhea	Measured by daily diary completion via mobile app	Baseline, 1, 3 and 6 months
Secondary	Change in doses of rescue pain medications	Measured by daily diary completion via mobile app	Baseline, 1, 3 and 6 months
Secondary	Change from baseline in mean daily pain score	Measured by daily diary completion via mobile app	Baseline, 1, 3 and 6 months